| Literature DB >> 28263777 |
Deepika Arora1, Pradeep Kumar Sharma2, Mohammed Haris Siddiqui3, Yogeshwer Shukla4.
Abstract
Among the various programmed cell death (PCD) pathways, "Necroptosis" has gained much importance as a novel paradigm of cell death. This pathway has emerged as a backup mechanism when physiologically conserved PCD (apoptosis) is non-functional either genetically or pathogenically. The expanding spectrum of necroptosis from physiological development to diverse patho-physiological disorders, including xenobiotics-mediated toxicity has now grabbed the attention worldwide. The efficient role of necroptosis regulators in disease development and management are under constant examination. In fact, few regulators (e.g. MLKL) have already paved their way towards clinical trials and others are in queue. In this review, emphasis has been paid to the various contributing factors and molecular switches that can regulate necroptosis. Here we linked the overview of current knowledge of this enigmatic signaling with magnitude of therapeutics that may underpin the opportunities for novel therapeutic approaches to suppress the pathogenesis of necroptosis-driven disorders.Entities:
Keywords: Inflammation; Necroptosis; Programmed cell death; Therapeutics
Mesh:
Substances:
Year: 2017 PMID: 28263777 DOI: 10.1016/j.biochi.2017.02.015
Source DB: PubMed Journal: Biochimie ISSN: 0300-9084 Impact factor: 4.079